The pharmacological management of PD is complex. Monoamine Oxidase-B (MAO-B) inhibitors, dopamine receptor agonists and Levodopa represent first line treatment options [
1]. Typically younger individuals are treated with a MAO-B inhibitor (one daily dose), especially if symptoms are mild, or a dopamine receptor agonist (three daily doses) as first line intervention. Older (≥ 75 years) individuals, especially those with or at risk of cognitive impairment, may be treated with Levodopa as first line therapy [
7,
8]. Although management in early disease is usually adequate with monotherapy [
7,
8], more than half of people with PD take two to four anti-parkinsonian medications three to four times daily [
9,
10]. This is because multiple drug classes are warranted as PD progresses [
11‐
14]. Furthermore, each drug may have different dosing schedules, further complicating regimens [
9]. Catechol-O-Methyltransferase inhibitors can supplement Levodopa adding further complexity. Increasing doses and/or dosage frequency may also be required to adequately manage worsening symptoms in advanced stages [
14]. With advancing disease, the therapeutic window narrows and becomes reliant on more frequent and specific interval dosing to maintain adequate treatment effect and avoid motor fluctuations [
7,
15]. Some people with advanced PD can take as many as ten doses a day in order to manage fluctuations [
8,
16]. Dyskinesias (involuntary movements) associated with long-term Levodopa use may also require remediation in later PD [
16]. Additionally, specific non-motor complications necessitate further drug use [
4,
14].